Panel Discussion: Overcoming Design Challenges in Next-Generation Oligonucleotides to Maximize Selectivity, Potency & Clinical Impact

Time: 9:00 am
day: Conference Day Two

Details:

• What design strategies are most effective in mitigating off-target effects?
• How do teams prioritize stability vs. delivery vs. potency?
• What are the emerging trends in oligonucleotide chemistry for next-generation therapeutics?

Speakers:

Ganesh Iyer Ganesh Iyer is the CEO and Founder of Opprtna Therapeutics, advancing therapeutic aptamers targeting critical proteins in neurodegenerative diseases and oncology. With a Ph.D. in Read more

Pawan Kumar Pawan Kumar, Ph.D., is Director of Oligonucleotide Chemistry at BioMarin Pharmaceutical. An experienced oligonucleotide and bioconjugate chemist, he has contributed extensively to therapeutic oligonucleotide development, Read more

Puneet Anand

Utsav Saxena Utsav Saxena, Ph.D., is Head of Systems Biology at Novo Nordisk. He is a cellular and molecular biologist with broad experience in cancer biology and Read more

Jim Weterings